139 related articles for article (PubMed ID: 38394807)
1. Detection of EGFR T790M mutation using liquid biopsy for non-small cell lung cancer: Utility of droplet digital polymerase chain reaction vs. cobas real-time polymerase chain reaction.
Zungsontiporn N; Ouwongprayoon P; Boonsirikamchai P; Leelayuwatanakul N; Vinayanuwattikun C; Moonai K; Khongkhaduead E; Thorner PS; Shuangshoti S; Teerapakpinyo C
Pathol Res Pract; 2024 Mar; 255():155213. PubMed ID: 38394807
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer.
Papadimitrakopoulou VA; Han JY; Ahn MJ; Ramalingam SS; Delmonte A; Hsia TC; Laskin J; Kim SW; He Y; Tsai CM; Hida T; Maemondo M; Kato T; Jenkins S; Patel S; Huang X; Laus G; Markovets A; Thress KS; Wu YL; Mok T
Cancer; 2020 Jan; 126(2):373-380. PubMed ID: 31769875
[TBL] [Abstract][Full Text] [Related]
3. The impact of EGFR T790M mutation status following the development of Osimertinib resistance on the efficacy of Osimertinib in non-small cell lung cancer: A meta-analysis.
Guo L; Zhou G; Huang M; Tang K; Xu J; Chen J
Clin Respir J; 2024 Apr; 18(4):e13748. PubMed ID: 38584122
[TBL] [Abstract][Full Text] [Related]
4. EGFR T790M detection and osimertinib treatment response evaluation by liquid biopsy in lung adenocarcinoma patients with acquired resistance to first generation EGFR tyrosine kinase inhibitors.
Li C; Jia R; Liu H; Zhang B; Wang C
Diagn Pathol; 2018 Aug; 13(1):49. PubMed ID: 30103780
[TBL] [Abstract][Full Text] [Related]
5. Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M-positive non-small cell lung cancer: West Japan Oncology Group 8815L/LPS study.
Takahama T; Azuma K; Shimokawa M; Takeda M; Ishii H; Kato T; Saito H; Daga H; Tsuboguchi Y; Okamoto I; Otsubo K; Akamatsu H; Teraoka S; Takahashi T; Ono A; Ohira T; Yokoyama T; Sakai K; Yamamoto N; Nishio K; Nakagawa K
Cancer; 2020 Jan; 126(9):1940-1948. PubMed ID: 32022929
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive analysis of EGFR T790M detection by ddPCR and ARMS-PCR and the effect of mutant abundance on the efficacy of osimertinib in NSCLC patients.
Li Y; Xu Y; Wu X; He C; Liu Q; Wang F
J Thorac Dis; 2019 Jul; 11(7):3004-3014. PubMed ID: 31463130
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of osimertinib in patients with EGFR-mutation positive non-small cell lung cancer with malignant pleural effusion.
Kiritani A; Amino Y; Uchibori K; Akita T; Harutani Y; Ogusu S; Tsugitomi R; Manabe R; Ariyasu R; Kitazono S; Yanagitani N; Nishio M
Thorac Cancer; 2024 Feb; 15(5):402-409. PubMed ID: 38226415
[TBL] [Abstract][Full Text] [Related]
8. [Comparison of epidermal growth factor receptor (EGFR) gene T790M mutation by droplet digital PCR and Super-ARMS PCR in plasma ctDNA samples of non-small cell lung cancer patients with the resistance to EGFR-tyrosine kinase inhibitor].
Cao ZY; Wu W; Hou LK; Zhang W; Gao CX; Wu CY; Zhang LP
Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):910-914. PubMed ID: 30522170
[No Abstract] [Full Text] [Related]
9. Predictive impact of low-frequency pretreatment T790M mutation in patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors.
Matsumoto Y; Sawa K; Fukui M; Oyanagi J; Yoshimoto N; Suzumura T; Watanabe T; Kaneda H; Mitsuoka S; Asai K; Kimura T; Yamamoto N; Hirata K; Koh Y; Kawaguchi T
Lung Cancer; 2020 Jan; 139():80-88. PubMed ID: 31751804
[TBL] [Abstract][Full Text] [Related]
10. Osimertinib readministration for central nervous system metastases in non-small cell lung cancer positive for EGFR activating mutations.
Inutsuka Y; Iwama E; Shiraishi Y; Yoneshima Y; Shibahara D; Tanaka K; Okamoto I
Respir Investig; 2024 May; 62(3):334-338. PubMed ID: 38412569
[TBL] [Abstract][Full Text] [Related]
11. Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E.
Chen MF; Song Z; Yu HA; Sequist LV; Lovly CM; Mitchell EP; Moscow JA; Gray RJ; Wang V; McShane LM; Rubinstein LV; Patton DR; Williams PM; Hamilton SR; Umemura Y; Tricoli JV; Conley BA; Arteaga CL; Harris LN; O'Dwyer PJ; Chen AP; Flaherty KT
JCO Precis Oncol; 2024 Apr; 8():e2300454. PubMed ID: 38591867
[TBL] [Abstract][Full Text] [Related]
12. The correlation between the abundance of EGFR T790M mutation and osimertinib response in advanced non-small cell lung cancer.
Pan G; Chen K; Yu X; Sheng J; Fan Y
Transl Cancer Res; 2021 Jun; 10(6):2895-2905. PubMed ID: 35116599
[TBL] [Abstract][Full Text] [Related]
13. Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced
Remon J; Besse B; Aix SP; Callejo A; Al-Rabi K; Bernabe R; Greillier L; Majem M; Reguart N; Monnet I; Cousin S; Garrido P; Robinet G; Campelo RG; Madroszyk A; Mazières J; Curcio H; Wasąg B; Pretzenbacher Y; Grillet F; Dingemans AC; Dziadziuszko R
J Clin Oncol; 2024 Apr; 42(12):1350-1356. PubMed ID: 38324744
[No Abstract] [Full Text] [Related]
14. Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first- or second-generation tyrosine kinase inhibitors.
Huang CT; Lin CA; Su TJ; Yang CY; Tsai TH; Hsu CL; Liao WY; Chen KY; Ho CC; Yu CJ
BMC Cancer; 2023 Mar; 23(1):234. PubMed ID: 36915101
[TBL] [Abstract][Full Text] [Related]
15. Monitoring epidermal growth factor receptor C797S mutation in Japanese non-small cell lung cancer patients with serial cell-free DNA evaluation using digital droplet PCR.
Ariyasu R; Uchibori K; Sasaki T; Tsukahara M; Kiyotani K; Yoshida R; Ono Y; Kitazono S; Ninomiya H; Ishikawa Y; Mizukami Y; Yanagitani N; Fujita N; Nishio M; Katayama R
Cancer Sci; 2021 Jun; 112(6):2371-2380. PubMed ID: 33686722
[TBL] [Abstract][Full Text] [Related]
16. A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR-TKI resistance.
Wang W; Song Z; Zhang Y
Cancer Med; 2017 Jan; 6(1):154-162. PubMed ID: 28000387
[TBL] [Abstract][Full Text] [Related]
17. EGFR Mutations in Cell-free Plasma DNA from Patients with Advanced Lung Adenocarcinoma: Improved Detection by Droplet Digital PCR.
Buder A; Setinek U; Hochmair MJ; Schwab S; Kirchbacher K; Keck A; Burghuber OC; Pirker R; Filipits M
Target Oncol; 2019 Apr; 14(2):197-203. PubMed ID: 30810887
[TBL] [Abstract][Full Text] [Related]
18. The detection of primary and secondary EGFR mutations using droplet digital PCR in patients with nonsmall cell lung cancer.
Suryavanshi M; Mehta A; Panigrahi MK; Jaipuria J; Saifi M; Jain K; Kumar D; Verma H; Sharma SK; Batra U; Dutta K; Talwar V; Doval DC
Lung India; 2018; 35(5):384-389. PubMed ID: 30168456
[TBL] [Abstract][Full Text] [Related]
19. Co-Occurring Alterations in Multiple Tumor Suppressor Genes Are Associated With Worse Outcomes in Patients With EGFR-Mutant Lung Cancer.
Stockhammer P; Grant M; Wurtz A; Foggetti G; Expósito F; Gu J; Zhao H; Choi J; Chung S; Li F; Walther Z; Dietz J; Duffield E; Gettinger S; Politi K; Goldberg SB
J Thorac Oncol; 2024 Feb; 19(2):240-251. PubMed ID: 37806385
[TBL] [Abstract][Full Text] [Related]
20. Application of ddPCR in detection of the status and abundance of EGFR T790M mutation in the plasma samples of non-small cell lung cancer patients.
Zhang H; Hu Y; Wang Y; Song X; Hu Y; Ma L; Yang X; Li K; Qin N; Wang J; Lv J; Li X; Zhang X; Zhang Q; Wu Y; Yao G; Zhang S
Front Oncol; 2022; 12():942123. PubMed ID: 36776375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]